BCL2-specific inhibitor ABT-199 synergizes strongly with cytarabine against the early immature LOUCY cell line but not more-differentiated T-ALL cell lines

Leukemia

Volumn 28, Issue 5, 2014, Pages 1145-1148

  Anderson, N M ^a   Harrold, I ^a   Mansour, M R ^b,c   Sanda, T ^d   McKeown, M ^b   Nagykary, N ^a   Bradner, J E ^b   Lan Zhang, G ^e   Look, A T ^b   Feng, H ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^e Boston University   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; LIPOCORTIN 5; NAVITOCLAX; PROPIDIUM IODIDE; RAPAMYCIN; VENETOCLAX; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CELL VIABILITY; CHRONIC LYMPHATIC LEUKEMIA; DRUG EFFECT; GENE EXPRESSION; GENE MUTATION; HUMAN; IC 50; IMMUNOPHENOTYPING; IN VITRO STUDY; IN VIVO STUDY; JURKAT CELL LINE; LETTER; LEUKEMIA CELL LINE; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRE T LYMPHOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECURRENCE RISK; S PHASE CELL CYCLE CHECKPOINT; T CELL ACUTE LYMPHOBLASTIC LEUKEMIA CELL LINE; T CELL LEUKEMIA; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; BICYCLO COMPOUNDS, HETEROCYCLIC; CELL DIFFERENTIATION; CELL LINE, TUMOR; CYTARABINE; DRUG SYNERGISM; HUMANS; PRECURSOR T-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROTO-ONCOGENE PROTEINS C-BCL-2; SULFONAMIDES;

EID: 84899950957     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2013.377     Document Type: Letter

References (12)

1. Pui CH, Robison LL, Look AT. Acute lymphoblastic leukaemia. Lancet 2008; 371: 1030-1043.
2. Goldberg JM, Silverman LB, Levy DE, Dalton VK, Gelber RD, Lehmann L. et al. Childhood T-cell acute lymphoblastic leukemia: The Dana-Farber Cancer Institute acute lymphoblastic leukemia consortium experience. J Clin Oncol 2003; 21: 3616-3622.
3. Coustan-Smith E, Mullighan CG, Onciu M, Behm FG, Raimondi SC, Pei D. et al. Early T-cell precursor leukaemia: A subtype of very high-risk acute lymphoblastic leukaemia. Lancet Oncol 2009; 10: 147-156.
4. Van Vlierberghe P, Ambesi-Impiombato A, Perez-Garcia A, Haydu JE, Rigo I, Hadler M. et al. ETV6 mutations in early immature human T cell leukemias. J Exp Med 2011; 208: 2571-2579.
5. Rothenberg EV, Moore JE, Yui MA. Launching the T-cell-lineage developmental programme. Nature reviews. Immunology 2008; 8: 9-21.
6. Zhang J, Ding L, Holmfeldt L, Wu G, Heatley SL, Payne-Turner D. et al. The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. Nature 2012; 481: 157-163.
7. Davids MS, Letai A. Targeting the B-cell lymphoma/leukemia 2 family in cancer. J Clin Oncol 2012; 30: 3127-3135.
8. Zhang L, Ming L, Yu J. BH3 mimetics to improve cancer therapy; mechanisms and examples. Drug Resist Updat 2007; 10: 207-217.
9. Tse C, Shoemaker AR, Adickes J, Anderson MG, Chen J, Jin S. et al. ABT-263: A potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res 2008; 68: 3421-3428.
10. Gandhi L, Camidge DR, Ribeiro de Oliveira M, Bonomi P, Gandara D, Khaira D. et al. Phase I study of Navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors. J Clin Oncol 2011; 29: 909-916.
11. Vandenberg CJ, Cory S. ABT-199, a new Bcl-2-specific BH3 mimetic, has in vivo efficacy against aggressive Myc-driven mouse lymphomas without provoking thrombocytopenia. Blood 2013; 121: 2285-2288.
12. Souers AJ, Leverson JD, Boghaert ER, Ackler SL, Catron ND, Chen J. et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med 2013; 19: 202-208.